NL
DE
Wouter Hoefsloot, with Leiden University and Leiden UMC
Infections caused by mycobacteria kill more than 1.3 million people annually. Existing treatment requires taking multiple drugs over a 4-48 month period, which results in significant toxic side effects, social, and economic costs. Furthermore, these treatments are rapidly becoming ineffective due to antibiotic resistance. MycoLipid will address this global challenge by developing novel host-directed therapies (HDTs), that are less susceptible to antibiotic resistance and can improve the safety and efficacy of existing drugs. These HDTs will boost the antibacterial response of immune cells and deprive infecting bacteria of nutrients by targeting host-lipid metabolism. MycoLipid’s team of experienced scientists and clinicians will use an innovative combination of state-of-the-art technologies to identify new drug targets and drug candidates, and validate these using patient-derived samples, thus ensuring groundbreaking advances in science and translation to improved patient treatments.
-
Want to know more about these subjects? Click on the buttons below for more news.
